◒

Gabapentinoids: Difference between revisions

From WikiMSK

No edit summary
m (I think gabapentin might have been a typo and the intention was to write gabapentin. That seems to be the conclusion of Deery et al in the paper below.)
 
(4 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{partial}}
'''Gabapentin'''{{NZF|code=2629}} and '''pregabalin'''{{NZF|code=2631}} are together referred to as gabapentinoids. They were originally designed as antiepileptics however they have been used in a very wide range of conditions including pain conditions despite limited evidence for use.
==Gabapentin==
==Gabapentin==
* First discovered in 1970s in an attempt to create a GABA analogue
* First discovered in 1970s in an attempt to create a GABA analogue
Line 4: Line 7:
* Later discovered to act on α2δ subunits of voltage-dependent calcium channels to reduce calcium influx
* Later discovered to act on α2δ subunits of voltage-dependent calcium channels to reduce calcium influx
** Precise mechanism of analgesia unclear
** Precise mechanism of analgesia unclear
* Inhibits release of excitatory neurotransmitters: glutamate, NA, substance P
* Inhibits release of excitatory neurotransmitters: glutamate, NA, substance P
* Medsafe licenced for: neuropathic pain, adjunct anti-epileptic
* Medsafe licenced for: neuropathic pain, adjunct anti-epileptic
Line 14: Line 16:


==Pregabalin==
==Pregabalin==
* Similar to gabapentin. Binds to α2δ subunits of voltage-dependent calcium channels to reduce calcium influx
* Similar to gabapentin. Binds to α2δ subunits of voltage-dependent calcium channels to reduce calcium influx
** Inhibits release of excitatory neurotransmitters: glutamate, NA, substance P
** Inhibits release of excitatory neurotransmitters: glutamate, NA, substance P
Line 23: Line 24:
** Metabolism: minimal, no active metabolites
** Metabolism: minimal, no active metabolites
** Elimination: Renal excretion, half life 6.3 hours. Dose adjustment in renal impairment
** Elimination: Renal excretion, half life 6.3 hours. Dose adjustment in renal impairment


==Recommended prescribing: NZF==
==Recommended prescribing: NZF==
'''Gabapentin'''
'''Gabapentin'''


Line 47: Line 46:


==Evidence==
==Evidence==
'''Post-herpetic neuralgia, diabetic peripheral neuropathy and fibromyalgia
'''Post-herpetic neuralgia, diabetic peripheral neuropathy and fibromyalgia'''
'''
 
* Moderate quality evidence supports the use of gabapentinoids to improve pain in those with post-herpetic neuralgia or diabetic peripheral neuropathy compared with placebo <ref>{{#pmid:30673120}}</ref> <ref>{{#pmid:28597471}}</ref>
* Moderate quality evidence supports the use of gabapentinoids to improve pain in those with post-herpetic neuralgia or diabetic peripheral neuropathy compared with placebo <ref>{{#pmid:30673120}}</ref> <ref>{{#pmid:28597471}}</ref>
* High quality evidence supports the use of pregabalin to improve pain in those with fibromyalgia compared to placebo <ref>{{#pmid:27684492}}</ref>
* High quality evidence supports the use of pregabalin to improve pain in those with fibromyalgia compared to placebo <ref>{{#pmid:27684492}}</ref>
Line 55: Line 54:
** Moderate to severe post-herpetic neuralgia: Pregabalin 4, Gabapentin 7
** Moderate to severe post-herpetic neuralgia: Pregabalin 4, Gabapentin 7
** Moderate to severe diabetic peripheral neuropathy: Pregabalin 8, Gabapentin 6
** Moderate to severe diabetic peripheral neuropathy: Pregabalin 8, Gabapentin 6
** Fibromyalgia: Gabapentin 10
** Fibromyalgia: Pregabalin 10
* NNHs
 
** Moderate to severe neuropathic pain: Pregabalin 8, Gabapentin 7
[[File:Gabapentinoids vs placebo pain infographic Mathieson.png|600px]]


'''Low back and radicular pain'''
'''Low back and radicular pain'''
Line 66: Line 65:
** No difference in pain or disability at short, intermediate or long term follow up
** No difference in pain or disability at short, intermediate or long term follow up


[[File:Gabapentinoids vs placebo pain infographic Mathieson.png|600px]]
'''Other conditions'''
*Central neuropathic pain: Pregabalin 10 (95% CI 6-28), dose >1200mg daily
*Mixed: Pregabalin 7 (95% CI 5.4-11), dose 600mg daily
*Low quality studies showing no evidence of benefit in HIV neuropathy, neuropathic cancer pain, or polyneuropathy<ref>Derry S et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev 2019;1:CD007076. Wiffen PJ et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017;6:CD007938</ref>
 
==Adverse Effects==
*Pregabalin and gabapentin similar profiles
*Dose-dependent
*No serious adverse effects c.f placebo
*Some common effects:
**Dizziness
**Somnolence
**Blurred vision
**Fatigue
**Weight gain and peripheral oedema
**Dry mouth
**Ataxia
* NNHs
** Moderate to severe neuropathic pain: Pregabalin 8, Gabapentin 7


[[File:Gabapentinoids vs placebo adverse effects infographic Mathieson.png|600px]]
[[File:Gabapentinoids vs placebo adverse effects infographic Mathieson.png|600px]]
==Misuse and Abuse==
*Supratherapeutic doses cause relaxation and euphoria.
**Taken in combination with other drugs e.g opiates, potentiates effect
**May assist with opioid withdrawal symptoms
*Those with a history of substance abuse (in particular opioids) at increased risk abuse
*UK survey: Lifetime prevalence of misuse 1.1% for gabapentin, 0.5% pregabalin
*Increasing death rate as per Finland, Sweden, Germany, UK post-mortem toxicology registers (almost all cases due to multisubstance)
*Misused gabapentinoids obtained from healthcare providers in 63% cases (UK and US study)
*In 2019, UK re-classified as scheduled class C drug (1 month prescriptions and no repeats)
*Think twice when prescribing and check indication if patient presents already on it<ref>Hägg, S et al. Current Evidence on Abuse and Misuse of Gabapentinoids. Drug Safety 2020.43, 1235–1254</ref>
==Summary==
*First line treatment for some patients with post-herpetic neuralgia and diabetic [[Peripheral Neuropathy and Polyneuropathy|peripheral neuropathy]]
*Moderate to high quality evidence that not effective for [[Chronic Low Back Pain|low back pain]] or [[Lumbar Radicular Pain and Radiculopathy|radicular pain]]
*Limited evidence for other conditions


==References==
==References==
[[Category:Pharmacology]]

Latest revision as of 11:41, 30 June 2023

This article is still missing information.

GabapentinLink to NZF: 2629 and pregabalinLink to NZF: 2631 are together referred to as gabapentinoids. They were originally designed as antiepileptics however they have been used in a very wide range of conditions including pain conditions despite limited evidence for use.

Gabapentin

  • First discovered in 1970s in an attempt to create a GABA analogue
  • Whilst it resembles GABA, it does not act on the GABA receptor.
  • Later discovered to act on α2δ subunits of voltage-dependent calcium channels to reduce calcium influx
    • Precise mechanism of analgesia unclear
  • Inhibits release of excitatory neurotransmitters: glutamate, NA, substance P
  • Medsafe licenced for: neuropathic pain, adjunct anti-epileptic
  • Pharmacokinetics
    • Absorption: Saturable transporter so delayed peak levels at higher doses. Drugs that reduce motility (e.g opiates) increase bioavailability. Peak serum conc 3 hours
    • Distribution: Less lipophilic so requires active transport across the BBB
    • Metabolism: minimal
    • Elimination: Renal excretion, half life 5-7 hours. Dose adjustment in renal impairment

Pregabalin

  • Similar to gabapentin. Binds to α2δ subunits of voltage-dependent calcium channels to reduce calcium influx
    • Inhibits release of excitatory neurotransmitters: glutamate, NA, substance P
  • Medsafe licenced for: neuropathic pain, adjunct anti-epileptic
  • Pharmacokinetics
    • Absorption: Rapid absorption after oral administration. Peak serum conc 1h
    • Distribution: Less lipophilic so requires active transport across the BBB
    • Metabolism: minimal, no active metabolites
    • Elimination: Renal excretion, half life 6.3 hours. Dose adjustment in renal impairment

Recommended prescribing: NZF

Gabapentin

  • Day 1 300mg nocte
  • Day 2 300mg bd
  • Day 3 300mg tds
  • Then increase by 300mg every 2-3 days to max dose 3600mg daily

Pregabalin

  • Initially 75mg bd
  • 150mg bd after 3-7 days
  • Max dose 300mg bd after further 7 days

Titrate upwards until pain relief, side effects, or max dose reached

Remember to dose adjust for renal impairment: gabapentin if <80mL/min, pregabalin if <60mL/min

Caution in pregnancy (category B1); no clear data available,  use if benefits outweigh risks

Evidence

Post-herpetic neuralgia, diabetic peripheral neuropathy and fibromyalgia

  • Moderate quality evidence supports the use of gabapentinoids to improve pain in those with post-herpetic neuralgia or diabetic peripheral neuropathy compared with placebo [1] [2]
  • High quality evidence supports the use of pregabalin to improve pain in those with fibromyalgia compared to placebo [3]
  • The evidence for gabapentin in fibromyalgia is unclear because of the small number of trials and very low quality of evidence available [4]
  • NNTs
    • Moderate to severe post-herpetic neuralgia: Pregabalin 4, Gabapentin 7
    • Moderate to severe diabetic peripheral neuropathy: Pregabalin 8, Gabapentin 6
    • Fibromyalgia: Pregabalin 10

Gabapentinoids vs placebo pain infographic Mathieson.png

Low back and radicular pain

  • Systematic review and meta-analysis of 7 RCTs compared gabapentin and pregabalin to placebo. Judged moderate-high quality data [5]
  • Low back pain with or without lumbar radicular pain
    • No difference in pain or disability at short, intermediate or long term follow up
  • Lumbar radicular pain only
    • No difference in pain or disability at short, intermediate or long term follow up

Other conditions

  • Central neuropathic pain: Pregabalin 10 (95% CI 6-28), dose >1200mg daily
  • Mixed: Pregabalin 7 (95% CI 5.4-11), dose 600mg daily
  • Low quality studies showing no evidence of benefit in HIV neuropathy, neuropathic cancer pain, or polyneuropathy[6]

Adverse Effects

  • Pregabalin and gabapentin similar profiles
  • Dose-dependent
  • No serious adverse effects c.f placebo
  • Some common effects:
    • Dizziness
    • Somnolence
    • Blurred vision
    • Fatigue
    • Weight gain and peripheral oedema
    • Dry mouth
    • Ataxia
  • NNHs
    • Moderate to severe neuropathic pain: Pregabalin 8, Gabapentin 7

Gabapentinoids vs placebo adverse effects infographic Mathieson.png

Misuse and Abuse

  • Supratherapeutic doses cause relaxation and euphoria.
    • Taken in combination with other drugs e.g opiates, potentiates effect
    • May assist with opioid withdrawal symptoms
  • Those with a history of substance abuse (in particular opioids) at increased risk abuse
  • UK survey: Lifetime prevalence of misuse 1.1% for gabapentin, 0.5% pregabalin
  • Increasing death rate as per Finland, Sweden, Germany, UK post-mortem toxicology registers (almost all cases due to multisubstance)
  • Misused gabapentinoids obtained from healthcare providers in 63% cases (UK and US study)
  • In 2019, UK re-classified as scheduled class C drug (1 month prescriptions and no repeats)
  • Think twice when prescribing and check indication if patient presents already on it[7]

Summary

References

  1. ↑ Derry et al.. Pregabalin for neuropathic pain in adults. The Cochrane database of systematic reviews 2019. 1:CD007076. PMID: 30673120. DOI. Full Text.
  2. ↑ Wiffen et al.. Gabapentin for chronic neuropathic pain in adults. The Cochrane database of systematic reviews 2017. 6:CD007938. PMID: 28597471. DOI. Full Text.
  3. ↑ Derry et al.. Pregabalin for pain in fibromyalgia in adults. The Cochrane database of systematic reviews 2016. 9:CD011790. PMID: 27684492. DOI. Full Text.
  4. ↑ Cooper et al.. Gabapentin for fibromyalgia pain in adults. The Cochrane database of systematic reviews 2017. 1:CD012188. PMID: 28045473. DOI. Full Text.
  5. ↑ Enke et al.. Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2018. 190:E786-E793. PMID: 29970367. DOI. Full Text.
  6. ↑ Derry S et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev 2019;1:CD007076. Wiffen PJ et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017;6:CD007938
  7. ↑ Hägg, S et al. Current Evidence on Abuse and Misuse of Gabapentinoids. Drug Safety 2020.43, 1235–1254
Retrieved from ‘https://wikimsk.org/w/index.php?title=Gabapentinoids&oldid=21175’